Proteome Characterization Center: A Genoproteomics Pipeline for Cance Research

在本申请中，我们建议建立一个整合的蛋白质组表征中心（PCC）， 杰出的科学家和临床医生团队，以构建癌症生物标志物管道， 基因蛋白质组学方法。这个多学科小组由国际公认的专家组成， 临床肿瘤学、临床化学、癌症生物学、蛋白质组学技术、蛋白质组学/特定基因组学 生物信息学、生物统计学和实验设计、计量学/标准、技术优化、分析 建筑、项目管理和患者倡导。该计划是将基因组学与蛋白质组学联系起来 （基因蛋白质组学）。我们相信，基因组数据提供了一个非常有价值的分子途径， 识别可能有助于检测、鉴别诊断、结果 癌症的预测和治疗靶点。蛋白质组学方法将提供鉴定 蛋白质固有的独特特征，包括翻译后修饰，如糖基化 和磷酸化。我们提出了一个两步策略来构建一个基于证据的蛋白质组学生物标志物 卵巢癌和其他癌症的治疗管道。第一步是发现候选生物标志物， 基因组数据，包括使用质谱和基于亲和力的技术对人类进行TCGA 标本目标是全面表征肿瘤和正常生物标本，并识别其 蛋白质组成，以便系统地鉴定和优先考虑癌症相关蛋白质， 进行核查。第二步是使用靶向测定来验证这些候选物。目标是 使用优化和标准化的方法， high-throughput高通量technologies技术forthe discovered发现biomarkers生物标志物.虽然这项建议并不打算进行 大规模临床研究，我们相信最终的临床应用和性能 应明确规定这些测定的特性。凭借这支多学科的优秀团队， 我们的PCC为生物标志物的成功发现提供了最好的机会， 个性化癌症药物的验证。 相关性（参见说明）： 了解致癌作用中的分子网络对于开发成功的 降低癌症死亡率战略。基于从TCGA和其他基因组中鉴定的基因组改变， 来源，该提案将集中于开发临床有用的蛋白质生物标志物管道， 最先进的蛋白质组学技术用于个性化癌症治疗。

In this application, we propose to establish an integrated proteome characterization center (PCC) with an outstanding team of scientists and clinicians in order to construct a cancer biomarker pipeline using genoproteomic approaches. This multidisciplinary team consists of internationally recognized experts in clinical oncology, clinical chemistry, cancer biology, proteomic technologies, proteomics/genomics-specific bioinformatics, biostatistics and experimental design, metrology/standards, technology optimization, assay construction, project management and patient advocacy. The plan is to connect genomics with proteomics (genoproteomics). We believe that genomic data provides a highly valuable molecular route towards the identification of genes and pathways that could be useful forthe detection, differential diagnosis, outcome prediction and therapeutic targets of cancer. The proteomic approaches will provide the identification of unique features that are inherent to proteins including post-translational modifications, such as glycosylation and phosphorylation. We propose a two- step strategy to construct an evidence-based, proteomic biomarker pipeline for ovarian and other carcinomas. The first step is the discovery of candidate biomarkers from genomic data including TCGA using mass spectrometry and affinity based technologies on human specimens. The goal is to comprehensively characterize tumor and normal biospecimens and identify their protein composition in order to systematically identify and prioritize cancer-related proteins for advancement to verification. The second step is the verification of these candidates using targeted assays. The goal is to generate accurate, reproducible, sensitive, quantitative, multiplex assays using optimized and standardized high-throughput technologies forthe discovered biomarkers. While this proposal is not intended to conduct large scale clinical studies, we believe that the ultimate clinical application and the performance characteristics of these assays should be clearly defined. With this multidisciplinary team of outstanding scientists and clinicians, our PCC offers the best opportunity forthe success of biomarker discovery and verification for personalized cancer medicine. RELEVANCE (See instructions): Understanding the molecular networking in carcinogenesis is essential forthe development of a successful strategy to reduce cancer mortality. Based on the genomic alterations identified from TCGA and other sources, this proposal will focus on the development of a clinically useful protein biomarker pipeline using state-of-the art proteomics technologies for personalized cancer medicine.